AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
Log in

NASDAQ:KRYSKrystal Biotech Stock Price, Forecast & News

$53.81
+0.81 (+1.53 %)
(As of 05/26/2020 09:52 AM ET)
Add
Compare
Today's Range
$53.81
Now: $53.81
$54.66
50-Day Range
$37.03
MA: $49.71
$60.00
52-Week Range
$22.02
Now: $53.81
$66.85
Volume3,608 shs
Average Volume223,486 shs
Market Capitalization$935.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Read More
Krystal Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRYS
CUSIPN/A
Phone412-586-5830

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$11.72 per share

Profitability

Net Income$-19,090,000.00

Miscellaneous

Employees37
Market Cap$935.76 million
Next Earnings Date8/3/2020 (Estimated)
OptionableNot Optionable

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

How has Krystal Biotech's stock been impacted by COVID-19 (Coronavirus)?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KRYS stock has increased by 7.8% and is now trading at $53.81. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Krystal Biotech?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Krystal Biotech.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Krystal Biotech.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech Inc (NASDAQ:KRYS) released its quarterly earnings results on Monday, May, 4th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.13. View Krystal Biotech's earnings history.

What price target have analysts set for KRYS?

6 brokers have issued 1 year price targets for Krystal Biotech's stock. Their forecasts range from $60.00 to $100.00. On average, they expect Krystal Biotech's share price to reach $77.25 in the next year. This suggests a possible upside of 43.6% from the stock's current price. View analysts' price targets for Krystal Biotech.

What are Wall Street analysts saying about Krystal Biotech stock?

Here are some recent quotes from research analysts about Krystal Biotech stock:
  • 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (5/8/2020)
  • 2. Cowen Inc analysts commented, "On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated." (8/15/2019)
  • 3. Chardan Capital analysts commented, "We view the receipt of the FDA Therapy (RMAT) designation as a significant positive for the timelines on KB103. This news follows KB103 receiving the EMA Priority Medicines (PRIME) designation on 29 March. As we have noted, Krystal’s market cap is modest relative to companies with PRIME and/or RMAT/BTD designations. We again reiterate: We would not be surprised if Krystal’s market cap crosses $1 billion by 2020E. On today’s news, we update our detailed model, moving the probability of KB103 launch from 55% to 67%, leading to an increase in our 2030E KB103 sales estimate from $492.1 mm to $596.5 mm. With a reduction in our WACC from 12.4% to 11.9%, these changes lead to a 30% KRYS PT target increase, from $57.50 to $75. has demonstrated impressive wound closure data (albeit in small numbers of patients) in the GEM-1 and GEM-2 studies." (6/24/2019)

Has Krystal Biotech been receiving favorable news coverage?

Media stories about KRYS stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Krystal Biotech earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutKrystal Biotech.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a decrease in short interest in May. As of May 15th, there was short interest totaling 1,420,000 shares, a decrease of 6.0% from the April 30th total of 1,510,000 shares. Based on an average trading volume of 156,600 shares, the days-to-cover ratio is presently 9.1 days. Currently, 13.0% of the company's shares are short sold. View Krystal Biotech's Current Options Chain.

Who are some of Krystal Biotech's key competitors?

What other stocks do shareholders of Krystal Biotech own?

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:
  • Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)
  • Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)
  • Ms. Pooja Agarwal, VP of Product Devel. (Age 40)
  • Mr. Antony A. Riley, Chief Financial Officer (Age 51)
  • Ms. Gloria Lin, Accounting Mang.

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (6.05%), BlackRock Inc. (4.76%), State Street Corp (2.69%), Lord Abbett & CO. LLC (1.25%), Geode Capital Management LLC (0.96%) and Pictet Asset Management Ltd. (0.85%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan. View institutional ownership trends for Krystal Biotech.

Which major investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Invesco Ltd., Redmile Group LLC, Morgan Stanley, Alps Advisors Inc., Blair William & Co. IL, Parametric Portfolio Associates LLC, and Bank of New York Mellon Corp. Company insiders that have sold Krystal Biotech company stock in the last year include Daniel Janney, Krish S Krishnan, and Suma Krishnan. View insider buying and selling activity for Krystal Biotech.

Which major investors are buying Krystal Biotech stock?

KRYS stock was acquired by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Aviva PLC, Wells Fargo & Company MN, BlackRock Inc., Lord Abbett & CO. LLC, Atom Investors LP, JPMorgan Chase & Co., and Martingale Asset Management L P. Company insiders that have bought Krystal Biotech stock in the last two years include Krish S Krishnan, and Suma Krishnan. View insider buying and selling activity for Krystal Biotech.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $53.81.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $935.76 million. The company earns $-19,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.